文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

麻杏石甘汤合苇茎汤治疗重症急性呼吸综合征COVID-19患者的疗效:随机对照试验方案结构式摘要

Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-12-23

本研究为多中心、开放标签、2臂(1:1)随机对照试验,计划纳入温州3家医院140例18-85岁SARS-CoV-2阳性且有症状的轻中度住院患者。对照组接受常规支持治疗,中药组加用麻杏石甘汤合苇茎汤口服200 mL每日2次,连续14天。主要结局为随机化后14天内发热症状改善所需天数(体温<37°C)。

要点

  • 主要结局为14天内发热改善(体温<37°C)所需天数。
  • 中药组在常规支持治疗基础上加用麻杏石甘汤合苇茎汤200 mL每日2次口服,连续14天。
  • 计划样本量140例(每组70例),采用最小化法随机化并按肺炎严重程度平衡。

核心结论

  • 试验旨在验证在常规支持治疗基础上加用麻杏石甘汤合苇茎汤对COVID-19轻中度患者是否更有效。

研究设计与样本

  • 多中心、开放标签、2臂(1:1)随机对照试验,计划从温州3家医院招募140例18-85岁SARS-CoV-2阳性且有症状的轻中度住院患者。
  • 采用最小化法随机化,按肺炎严重程度平衡两组,每组70例;统计分析由对分组设盲的统计学教授执行。

主要发现

  • 本文件为试验方案摘要,未报告研究结果。

关键数值与推荐

  • 主要结局为随机化后14天内发热症状改善所需天数,发热改善定义为体温<37°C。
  • 次要结局包括中医证候评分、SARS-CoV-2核酸转阴时间、胸部X线改善比例及症状(发热、咳嗽、乏力、气短)恢复率。
  • 中医证候评分总分范围0-58分,分数越高表示病情越重。
  • 中药组干预为麻杏石甘汤合苇茎汤(含14味中药)口服200 mL每日2次,连续14天,加常规支持治疗。
  • 样本量估算基于中药组中位生存时间估计为3天、对照组延长1.5倍,采用Kaplan-Meier法和log-rank检验,设统计功效70%(单侧α=5%,β=30%)及10%脱落率,计划纳入140例。

临床怎么用

  • 该方案为临床研究设计提供参考,尚未提供疗效证据,不能直接用于临床实践决策。

局限性

  • 开放标签设计可能引入实施与测量偏倚。
  • 样本量基于既往研究的生存时间估计,可能存在不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to test our expectation that additional administration of Traditional Chinese medicine (TCM), maxingshigan-weijing decoction, is more effective in the management of COVID-19 patients compared to those treated with routine supportive care alone. TRIAL DESIGN: This is a multicenter, open-label 2-arm (1:1 ratio) randomized controlled trial. PARTICIPANTS: Patients will be recruited from 3 hospitals in Wenzhou China: the First Affiliated Hospital of Wenzhou Medical University, the Second Affiliated Hospital of Wenzhou Medical University and Wenzhou Center Hospital. The inclusion and exclusion criteria are as follows: Inclusion criteria 1. Participants are 18-85 years of age, either male or female. 2. Diagnosed as positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3. Symptomatic. Mild (mild clinical symptoms without signs of pneumonia in chest X-ray) and Moderate (fever or respiratory symptom with signs of pneumonia in chest X-ray) . 1. Signed the informed consent before treatment. 2. Agreed not to enroll in any other clinical trials. 3. Inpatients Exclusion criteria 1. < 18 or > 85 years old. 2. Pregnancy and lactation. 3. Serious heart, liver, kidney and hematopoietic system diseases, abnormal liver or kidney function. 4. Suffering from other known virus pneumonia. 5. Allergic to Chinese herbal medicine or suffering from allergies. 6. Critical patients (respiratory failure treated by mechanical ventilation or shock or multiple organ failure). INTERVENTION AND COMPARATOR: Patients in the control group will receive routine supportive clinically care including the therapies of anti-viral, anti-bacterial and ameliorating the related symptoms, while patients in TCM group will be asked to take maxingshigan-weijing decoction (composed of 14 Chinese herbal medicines), orally 200 mL 2 times daily, for 14 consecutive days in addition to routine supportive care as mentioned above. Maxingshigan-weijing decoction consists of 10 g of Herba Ephedra (Mahuang), 10 g of Amygdalus Communis Vas (Xingren), 45 g of Gypsum Fibrosum (Shigao), 30 g of Rhizoma phragmitis (Lugen), 20 g of Peach kernel (Taoren), 20 g of Winter Melon kernel (Dongguaren), 30 g of Trichosanthes Kirilowii Maxim (Gualou), 12 g of Pericarpium Citri Reticulatae (Chenpi), 12 g of Rhizoma Pinelliae (Jiangbanxia), 12 g of caulis bambusae in taeniis (Zhuru), 30 g of semen lepidii (Tingliz), 15 g of semen lepidii (Shichangpu), 10 g of curcuma zedoary (ezhu) and 5 g of Radix Glycyrrhizae (Gancao). MAIN OUTCOMES: The primary outcome will be the number of days until the clinical symptom of fever improves in the first 14 days of treatment following randomisation. Fever will be defined as an improvement when the temperature is less than 37°C. Secondary outcomes will be TCM Syndrome Scores, the time it takes until individuals have negative test results for SARS-CoV-2 nucleic acid, the proportion of cases with chest X-ray improvements and the rate of symptom (fever, cough, malaise, shortness of breath) recovery. TCM Syndrome Scoring System is a checklist covering 4 main, 7 secondary and 13 accompanying items. The 4 main items consisting of fever, cough, malaise and shortness of breath, use a four-point scale (0, 2, 4 and 6) depending on the severity; the 7 secondary items including dysphoria, diarrhea, pharyngalgia, expectoration, muscular soreness, nasal obstruction and rhinorrhoea use 0-3-point scale; the 13 accompanying items contain chest pain, headache, aversion to cold, dizziness, nausea and vomiting, anorexia, abdominal distension, dry mouth, anxiety, spontaneous sweating, insomnia, wheezing and blood tinged sputum, and each item is rated on 0-1 scale ( 0 stands for asymptomatic, 1 stands for symptomatic ). The total scores sum up to a range from 0 to 58, with higher scores indicating more severe levels of disease. RANDOMIZATION: Minimization method will be used, balancing the two arms for pneumonia severity. Patients are randomized (1:1 ratio) to each group. Clinical researchers will get a random sequence number which is automatically generated by a random number generator (IBM Corp., Armonk, NY, USA), and sequentially number them in an opaque envelope. Researchers will open random allocation envelopes and assign participants accordingly. Eligible patients will be randomly divided into a routine supportive care group and a routine supportive care plus oral administration of traditional Chinese medicine group, with 70 patients in each group. BLINDING (MASKING): This is an open-label study. The statistical analysis will be carried out by the Professor of Statistics at Wenzhou Medical University, who is blinded to patient allocation. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The previous study reported the efficacy of TCM for COVID-19 and H1N1 influenza patients, the median survival time in the TCM group is estimated as 3 days; this time will be 1.5 times longer in the control group. Accordingly, Kaplan-Meier method and log-rank test will be used. And assuming a statistical power of 70% (one-sided type-1 error of α = 5%, β = 30%) and a rate of withdrawal and loss to follow-up of 10%, we plan to include 140 participants in both groups ( TCM group = 70, control group = 70). TRIAL STATUS: The trial protocol is Version 2.0, October 14, 2020. Recruitment began March, 2020, and is anticipated to be completed by December 31, 2020. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2000030759 . Registered on 13 March 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zeng C, Yuan Z, Pan X, et al. Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 33357239. doi:10.1186/s13063-020-04970-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。